Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
Background - PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab versus placebo plus bevacizumab in newly diagnosed, advanced ovarian cancer. We report the prespecified main second progression-free survival (P...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
5 September 2022
|
| In: |
European journal of cancer
Year: 2022, Jahrgang: 174, Pages: 221-231 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2022.07.022 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2022.07.022 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804922004476 
|
| Verfasserangaben: | Antonio González-Martín, Christophe Desauw, Florian Heitz, Claire Cropet, Piera Gargiulo, Regina Berger, Hiroyuki Ochi, Ignace Vergote, Nicoletta Colombo, Mansoor R. Mirza, Youssef Tazi, Ulrich Canzler, Claudio Zamagni, Eva M. Guerra-Alia, Charles B. Levaché, Frederik Marmé, Fernando Bazan, Nikolaus de Gregorio, Nadine Dohollou, Peter A. Fasching, Giovanni Scambia, María J. Rubio-Pérez, Tsveta Milenkova, Cristina Costan, Patricia Pautier, Isabelle Ray-Coquard on behalf ofthe PAOLA1/ENGOT-ov25 investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1830900803 | ||
| 003 | DE-627 | ||
| 005 | 20240326080357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230112s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2022.07.022 |2 doi | |
| 035 | |a (DE-627)1830900803 | ||
| 035 | |a (DE-599)KXP1830900803 | ||
| 035 | |a (OCoLC)1361669585 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a González Martín, Antonio |e VerfasserIn |0 (DE-588)1192920910 |0 (DE-627)1671440153 |4 aut | |
| 245 | 1 | 0 | |a Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer |b main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial |c Antonio González-Martín, Christophe Desauw, Florian Heitz, Claire Cropet, Piera Gargiulo, Regina Berger, Hiroyuki Ochi, Ignace Vergote, Nicoletta Colombo, Mansoor R. Mirza, Youssef Tazi, Ulrich Canzler, Claudio Zamagni, Eva M. Guerra-Alia, Charles B. Levaché, Frederik Marmé, Fernando Bazan, Nikolaus de Gregorio, Nadine Dohollou, Peter A. Fasching, Giovanni Scambia, María J. Rubio-Pérez, Tsveta Milenkova, Cristina Costan, Patricia Pautier, Isabelle Ray-Coquard on behalf ofthe PAOLA1/ENGOT-ov25 investigators |
| 264 | 1 | |c 5 September 2022 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.01.2023 | ||
| 520 | |a Background - PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab versus placebo plus bevacizumab in newly diagnosed, advanced ovarian cancer. We report the prespecified main second progression-free survival (PFS2) analysis for PAOLA-1. - Methods - This randomised, double-blind, phase III trial was conducted in 11 countries. Eligible patients had newly diagnosed, advanced, high-grade ovarian cancer and were in response after first-line platinum-based chemotherapy plus bevacizumab. Patients were randomised 2:1 to olaparib (300 mg twice daily) or placebo for up to 24 months; all patients received bevacizumab (15 mg/kg every 3 weeks) for up to 15 months. Primary PFS end-point was reported previously. Time from randomisation to second disease progression or death was a key secondary end-point included in the hierarchical-testing procedure. - Results - After a median follow-up of 35.5 months and 36.5 months, respectively, median PFS2 was 36.5 months (olaparib plus bevacizumab) and 32.6 months (placebo plus bevacizumab), hazard ratio 0.78; 95% confidence interval (CI) 0.64-0.95; P = 0.0125. Median time to second subsequent therapy or death was 38.2 months (olaparib plus bevacizumab) and 31.5 months (placebo plus bevacizumab), hazard ratio 0.78; 95% CI 0.64-0.95; P = 0.0115. Seventy-two (27%) patients in the placebo plus bevacizumab group received a poly(ADP-ribose) polymerase inhibitor as first subsequent therapy. No new safety signals were observed for olaparib plus bevacizumab. - Conclusion - In newly diagnosed, advanced ovarian cancer, maintenance olaparib plus bevacizumab provided continued benefit beyond first progression, with a significant PFS2 improvement and a time to second subsequent therapy or death delay versus placebo plus bevacizumab. | ||
| 650 | 4 | |a Antiangiogenic agent | |
| 650 | 4 | |a Bevacizumab | |
| 650 | 4 | |a Olaparib | |
| 650 | 4 | |a Ovarian cancer | |
| 650 | 4 | |a PARP inhibitor | |
| 650 | 4 | |a Second progression-free survival | |
| 700 | 1 | |a Desauw, Christophe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heitz, Florian |d 1976- |e VerfasserIn |0 (DE-588)13714220X |0 (DE-627)590336347 |0 (DE-576)30237051X |4 aut | |
| 700 | 1 | |a Cropet, Claire |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gargiulo, Piera |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berger, Regina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ochi, Hiroyuki |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vergote, Ignace |e VerfasserIn |4 aut | |
| 700 | 1 | |a Colombo, Nicoletta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mirza, Mansoor R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tazi, Youssef |e VerfasserIn |4 aut | |
| 700 | 1 | |a Canzler, Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zamagni, Claudio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Guerra-Alia, Eva M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Levaché, Charles B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Bazan, Fernando |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Gregorio, Nikolaus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dohollou, Nadine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fasching, Peter A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scambia, Giovanni |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rubio-Pérez, María J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Milenkova, Tsveta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Costan, Cristina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pautier, Patricia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ray-Coquard, Isabelle |e VerfasserIn |0 (DE-588)1206566558 |0 (DE-627)1692653253 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 174(2022), Seite 221-231 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial |
| 773 | 1 | 8 | |g volume:174 |g year:2022 |g pages:221-231 |g extent:11 |a Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2022.07.022 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804922004476 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230112 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 50000 |d 60000 |d 61300 |e 50000PM132561972 |e 60000PM132561972 |e 61300PM132561972 |k 0/50000/ |k 0/60000/ |k 1/60000/61300/ |p 16 | ||
| 999 | |a KXP-PPN1830900803 |e 4246404969 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Antonio","family":"González Martín","display":"González Martín, Antonio"},{"family":"Desauw","display":"Desauw, Christophe","role":"aut","given":"Christophe"},{"display":"Heitz, Florian","family":"Heitz","role":"aut","given":"Florian"},{"role":"aut","given":"Claire","family":"Cropet","display":"Cropet, Claire"},{"role":"aut","given":"Piera","display":"Gargiulo, Piera","family":"Gargiulo"},{"display":"Berger, Regina","family":"Berger","given":"Regina","role":"aut"},{"role":"aut","given":"Hiroyuki","family":"Ochi","display":"Ochi, Hiroyuki"},{"role":"aut","given":"Ignace","family":"Vergote","display":"Vergote, Ignace"},{"family":"Colombo","display":"Colombo, Nicoletta","role":"aut","given":"Nicoletta"},{"display":"Mirza, Mansoor R.","family":"Mirza","role":"aut","given":"Mansoor R."},{"family":"Tazi","display":"Tazi, Youssef","given":"Youssef","role":"aut"},{"family":"Canzler","display":"Canzler, Ulrich","role":"aut","given":"Ulrich"},{"family":"Zamagni","display":"Zamagni, Claudio","role":"aut","given":"Claudio"},{"family":"Guerra-Alia","display":"Guerra-Alia, Eva M.","role":"aut","given":"Eva M."},{"role":"aut","given":"Charles B.","family":"Levaché","display":"Levaché, Charles B."},{"given":"Frederik","role":"aut","display":"Marmé, Frederik","family":"Marmé"},{"role":"aut","given":"Fernando","family":"Bazan","display":"Bazan, Fernando"},{"given":"Nikolaus","role":"aut","family":"de Gregorio","display":"de Gregorio, Nikolaus"},{"role":"aut","given":"Nadine","family":"Dohollou","display":"Dohollou, Nadine"},{"role":"aut","given":"Peter A.","family":"Fasching","display":"Fasching, Peter A."},{"role":"aut","given":"Giovanni","family":"Scambia","display":"Scambia, Giovanni"},{"family":"Rubio-Pérez","display":"Rubio-Pérez, María J.","role":"aut","given":"María J."},{"display":"Milenkova, Tsveta","family":"Milenkova","role":"aut","given":"Tsveta"},{"display":"Costan, Cristina","family":"Costan","role":"aut","given":"Cristina"},{"family":"Pautier","display":"Pautier, Patricia","role":"aut","given":"Patricia"},{"given":"Isabelle","role":"aut","family":"Ray-Coquard","display":"Ray-Coquard, Isabelle"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer","subtitle":"main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial","title_sort":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer"}],"note":["Gesehen am 12.01.2023"],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"5 September 2022"}],"id":{"eki":["1830900803"],"doi":["10.1016/j.ejca.2022.07.022"]},"physDesc":[{"extent":"11 S."}],"name":{"displayForm":["Antonio González-Martín, Christophe Desauw, Florian Heitz, Claire Cropet, Piera Gargiulo, Regina Berger, Hiroyuki Ochi, Ignace Vergote, Nicoletta Colombo, Mansoor R. Mirza, Youssef Tazi, Ulrich Canzler, Claudio Zamagni, Eva M. Guerra-Alia, Charles B. Levaché, Frederik Marmé, Fernando Bazan, Nikolaus de Gregorio, Nadine Dohollou, Peter A. Fasching, Giovanni Scambia, María J. Rubio-Pérez, Tsveta Milenkova, Cristina Costan, Patricia Pautier, Isabelle Ray-Coquard on behalf ofthe PAOLA1/ENGOT-ov25 investigators"]},"recId":"1830900803","relHost":[{"disp":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trialEuropean journal of cancer","type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Elsevier ; Pergamon Press","dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"pubHistory":["28.1992 -"],"title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"id":{"issn":["1879-0852"],"zdb":["1468190-0"],"eki":["266883400"]},"recId":"266883400","corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"display":"European Association for Cancer Research","role":"isb"},{"display":"European School of Oncology","role":"isb"}],"titleAlt":[{"title":"EJC online"}],"part":{"volume":"174","text":"174(2022), Seite 221-231","extent":"11","year":"2022","pages":"221-231"},"language":["eng"]}]} | ||
| SRT | |a GONZALEZMAMAINTENANC5202 | ||